Sarah, a 52-year-old cancer patient, gets standard chemotherapy under one approach, but precision oncology reveals thousands of biomarkers in her tumor. By identifying the molecular switches driving her cancer, doctors can recruit her immune system and design a personalized mix of therapies instead of following a generic protocol.
Let me put this together with a simple story. We'll call her Sarah. She's age 52 and she has a standard of care path. So Sarah started standard chemotherapy regimen based on the National Comprehensive Cancer Network guidelines. Everything is by the book. This is board certified oncology standard of care. The biology is never fully mapped. Now she has a second path, precision oncology. Sarah now has thousands of markers built around her precision mapping. We, we can find the mutations, the RNA exit paths. What are the switches turning on the cancer, the heat maps. And take those cold tumors that are hiding and make them hot. So the immune system goes there and does the work. So now her plan includes careful on label, off label repurposed drugs, all custom built, including cellular biologics to get her immune system on board.
